Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Current status of metal stents for managing malignant ureteric obstruction..
BJU Int. 105(8), 1066-72.
(2010). Massive hematuria due to a congenital renal arteriovenous malformation mimicking a renal pelvis tumor: a case report..
J Med Case Rep. 2, 144.
(2008). Are metal ureteral stents indicated in cases of benign upper urinary tract obstruction?.
Indian J Urol. 27(3), 305-6.
(2011). Conservative management of post-radical prostatectomy incontinence..
Arch Esp Urol. 66(8), 763-75.
(2013). Non-visible asymptomatic haematuria: a review of the guidelines from the urologist's perspective..
Expert Rev Anticancer Ther. 17(3), 203-216.
(2017). Endoscopy-guided percutaneous nephrostolithotomy: benefits of ureteroscopic access and therapy..
J Endourol. 23(10), 1649-54.
(2009). The evolution of KTP laser vaporization of the prostate..
Yonsei Med J. 49(2), 189-99.
(2008). Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports..
J Med Case Rep. 5, 429.
(2011). Splenogonadal fusion mimicking a testis tumor..
J Postgrad Med. 60(2), 202-4.
(2014). Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction..
Ther Adv Urol. 11, 1756287219828971.
(2019). Secondary malignancies following radiotherapy for prostate cancer..
Ther Adv Urol. 2(3), 119-25.
(2010). Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis..
J Urol. 101097JU0000000000001639.
(2021). How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices..
Urologia. 87(3), 142-148.
(2020). Update on photoselective vaporization of the prostate..
Curr Urol Rep. 9(2), 106-12.
(2008). Is computed tomography mandatory for the detection of residual stone fragments after percutaneous nephrolithotomy?.
J Endourol. 27(11), 1341-8.
(2013). Palliative management of malignant upper urinary tract obstruction..
Hippokratia. 18(4), 292-7.
(2014). The era of active surveillance for low-risk.Prostate cancer is here..
Arch Esp Urol. 69(2), 49-51.
(2016). Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction..
World J Urol. 28(1), 3-8.
(2010). PVP versus HoLEP current outcomes and future strategies..
Arch Esp Urol. 63(2), 89-101.
(2010). The current role of high-intensity focused ultrasound for the management of radiation-recurrent prostate cancer..
Expert Rev Med Devices. 9(4), 401-8.
(2012). Combination Pharmacological Treatments for LUTS..
Curr Drug Targets. 16(11), 1162-4.
(2015). Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues..
J Endourol. 24(1), 129-42.
(2010). Prostate-specific antigen screening, why have the guidelines changed?.
Expert Rev Anticancer Ther. 14(11), 1277-81.
(2014). Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management..
ISRN Urol. 2013, 240108.
(2013). "Vanishing penis" and urinary retention due to locally destructive penile cancer..
ScientificWorldJournal. 9, 158-62.
(2009).